The featured article is a minireview titled ‘Recent Development in Alzheimer’s Disease Therapeutics’ by Michael Rafii and Paul Aisen and freely available here.
As the name suggests this is a brief review of therapeutic strategies in Alzheimer’s Disease which focuses on drugs which are undergoing clinical trials. The review does not cover the anticholinesterase inhibitors or memantine and I would also class this as an unstructured review as it does not include a methodology section but instead offers an insight oriented view of the field. Table 1 provides a useful overview of a number of drugs that have been trialled. The authors divide up the paper into sections on ABeta, tau phosphorylation and neuroprotection and in the process include some of the drugs that have generated wider interest recently including Bapineuzumab, Dimebon and Methylene Blue. While the article is brief it offers a useful overview of important candidates for treatment and provides brief narratives about drug developments as well as summaries of trials without the statistics. The discussion of the implications of passive versus active immunisation were particularly helpful. In summary this paper offers a useful overview of the field signposting interested readers to the relevant literature for further reading in this area. A number of competing interests are declared at the end of the article.
If you have any comments, you can leave them below or alternatively e-mail firstname.lastname@example.org
The comments made here represent the opinions of the author and do not represent the profession or any body/organisation. The comments made here are not meant as a source of medical advice and those seeking medical advice are advised to consult with their own doctor. The author is not responsible for the contents of any external sites that are linked to in this blog.